Moreover, FTO can also inhibit the expression of immune checkpoint genes, especially LILRB4, significantly weakening the self-renewal and reprogramming immune response of leukaemia stem cells/initiating cells, which has been proven to be an effective treatment strategy for AML [36, 37]. The gene discussed is LILRB4; the disease is acute myeloid leukemia.